Arzeda Corporation, founded in 2008 and based in Seattle, Washington, specializes in the development and commercialization of innovative enzymes and specialty chemical products. The company leverages advanced computational enzyme design technology to create designer proteins and enzymes tailored for diverse applications in polymers, pharmaceuticals, and industrial chemicals. By focusing on biocatalysis, Arzeda aims to provide clients with high-performance, cost-effective, and sustainable solutions that enhance their products. The company's expertise in synthetic biology positions it as a leader in the field, enabling the development of a robust portfolio that addresses the growing demand for advanced chemical products.
Kenota Health develops next-generation rapid point-of-care system intended to be used for allergy testing in humans. Kenota's diagnostic tools are safe, simple, and offer a cheaper alternative to allergy testing using a thorough non-invasive technology, enabling physicians to improve patient outcomes.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
uBiome, Inc. is a microbial genomics company based in San Francisco, California, founded in 2012. The company specializes in developing sequencing-based clinical microbiome tests, which include SmartGut, a test that identifies pathogenic and commensal microorganisms linked to infections, and SmartJane, a women's health screening test that assesses multiple conditions such as HPV and STIs. Additionally, uBiome offers Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. The firm aimed to empower patients and healthcare providers by providing insights into the human microbiome and its impact on health. However, uBiome faced financial difficulties, filing for Chapter 11 bankruptcy in September 2019, which was subsequently converted to Chapter 7 on October 11, 2019.
Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.
Lygos is a biotechnology company focused on providing sustainable solutions for renewable chemical production. Founded in 2011 and headquartered in Berkeley, California, Lygos engineers microbes to convert sugars into high-value industrial chemicals, emphasizing cost-effectiveness compared to traditional petrochemical processes. By utilizing advanced throughput screening and strain construction techniques, the company rapidly optimizes biological pathways to transform inexpensive and renewable feedstock into valuable chemical products. Lygos aims to replace persistent and often toxic chemicals with cleaner, more efficient alternatives, catering to business-to-business customers and fostering high-performing, sustainable solutions across the chemical industry.
Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.
NuMat Technologies, based in Skokie, Illinois, specializes in the design and integration of atomically engineered materials, specifically metal-organic frameworks (MOFs), into systems for gas delivery, separation, and purification. Founded in 2012, the company focuses on creating programmable chemistries that facilitate precision engineering and unlock new capabilities in resource management. NuMat's product portfolio includes ION-X, a solution for the safe storage and delivery of hazardous gases. The company offers a comprehensive platform for product commercialization that combines advanced material discovery software with rapid prototyping and system integration. This approach enables various industries, such as chemicals, electronics, and life sciences, to address sustainability and innovation goals through enhanced performance and cost-effective production methods.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company focused on discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. The company leverages an innovative drug discovery approach that significantly accelerates the development process and enhances success rates compared to traditional methods. Aria's technology enables it to build a robust pipeline of therapeutic candidates while also collaborating with biotechnology and pharmaceutical companies to jointly discover and develop new drug candidates. The company aims to address over 1,000 diseases, responding to the urgent need for breakthrough treatments for patients facing challenging health conditions. Incorporated in 2014 and based in Mountain View, California, Aria Pharmaceuticals is committed to advancing healthcare through its advanced drug discovery capabilities.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
3T Biosciences, Inc. is an immunotherapy company established in 2017 and based in Menlo Park, California. The company focuses on developing innovative treatments for cancer and other T-cell-mediated diseases by utilizing synthetic biology and machine learning technologies. Its approach involves discovering novel targets for drug development, which aims to enhance the effectiveness of cancer therapies. Through its research and development efforts, 3T Biosciences is committed to providing healthcare professionals with advanced treatment options for patients facing cancer-related illnesses.
Arzeda Corporation, founded in 2008 and based in Seattle, Washington, specializes in the development and commercialization of innovative enzymes and specialty chemical products. The company leverages advanced computational enzyme design technology to create designer proteins and enzymes tailored for diverse applications in polymers, pharmaceuticals, and industrial chemicals. By focusing on biocatalysis, Arzeda aims to provide clients with high-performance, cost-effective, and sustainable solutions that enhance their products. The company's expertise in synthetic biology positions it as a leader in the field, enabling the development of a robust portfolio that addresses the growing demand for advanced chemical products.
Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health.
The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs.
By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology.
The company was founded in 2012 and is based in Redwood City, California.
Lygos is a biotechnology company focused on providing sustainable solutions for renewable chemical production. Founded in 2011 and headquartered in Berkeley, California, Lygos engineers microbes to convert sugars into high-value industrial chemicals, emphasizing cost-effectiveness compared to traditional petrochemical processes. By utilizing advanced throughput screening and strain construction techniques, the company rapidly optimizes biological pathways to transform inexpensive and renewable feedstock into valuable chemical products. Lygos aims to replace persistent and often toxic chemicals with cleaner, more efficient alternatives, catering to business-to-business customers and fostering high-performing, sustainable solutions across the chemical industry.
Prospect Bio designs and develops biosensors for the detection of small molecules. The company is headquartered in Brisbane, California.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
MetaMixis Inc. is a biotechnology company based in Vancouver, Canada, founded in 2012. The company focuses on developing enzymes and metabolic pathways for microorganisms that produce chemicals. MetaMixis creates biosensors that leverage natural environmental processes to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a portfolio of enzymes and pathways capable of performing specific transformations. The founding team combines expertise in synthetic biology, environmental genomics, and bioinformatics, with the goal of advancing the bioeconomy through innovative enzyme and pathway discovery. The company has also established a knowledgeable board to guide its development and growth.
Kenota Health develops next-generation rapid point-of-care system intended to be used for allergy testing in humans. Kenota's diagnostic tools are safe, simple, and offer a cheaper alternative to allergy testing using a thorough non-invasive technology, enabling physicians to improve patient outcomes.
Kenota Health develops next-generation rapid point-of-care system intended to be used for allergy testing in humans. Kenota's diagnostic tools are safe, simple, and offer a cheaper alternative to allergy testing using a thorough non-invasive technology, enabling physicians to improve patient outcomes.
NuMat Technologies, based in Skokie, Illinois, specializes in the design and integration of atomically engineered materials, specifically metal-organic frameworks (MOFs), into systems for gas delivery, separation, and purification. Founded in 2012, the company focuses on creating programmable chemistries that facilitate precision engineering and unlock new capabilities in resource management. NuMat's product portfolio includes ION-X, a solution for the safe storage and delivery of hazardous gases. The company offers a comprehensive platform for product commercialization that combines advanced material discovery software with rapid prototyping and system integration. This approach enables various industries, such as chemicals, electronics, and life sciences, to address sustainability and innovation goals through enhanced performance and cost-effective production methods.
Non Equity Assistance in 2016
Mozio, Inc. operates an online airport transportation search and booking engine, enabling travelers to find and reserve various ground transportation options, including shared ride shuttles, private vans, taxis, limousines, and SUVs from airports across the globe. The platform aggregates local transportation services in regions such as the United States, Canada, Latin America, Europe, and Asia, simplifying the process of navigating from the airport to the final destination. Founded in 2012 and based in San Francisco, Mozio also offers API and affiliate programs, allowing travel websites and agents to sell transportation services. The company's mission is to enhance the travel experience by providing users with comprehensive information and the best deals for their ground transportation needs.
3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.
Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.
Planetary Resources is focused on the exploration and utilization of asteroids to unlock essential natural resources for humanity. The company provides services aimed at commercial deep space exploration, specifically targeting asteroids for raw materials such as water and precious metals. By extracting water from asteroids, Planetary Resources aims to support the in-space economy by producing rocket fuel and providing consumable water for future space habitation. This initiative is pivotal for enabling human expansion into space and contributing to the development of a sustainable space economy, ultimately helping humanity become a multi-planetary species.
Nanoly Bioscience, Inc. develops polymers that enable temperature-sensitive molecules to survive without refrigeration. It develops polymers that are blended with protein-based temperature-sensitive molecules, such as enzymes, vaccines, and others to enable them to survive without refrigeration while transportation. Nanoly Bioscience, Inc. was incorporated in 2012 and is headquartered in Denver, Colorado.
Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.
Viv Labs, Inc. is a technology company based in San Jose, California, specializing in artificial intelligence interfaces that facilitate interaction with various devices, services, and platforms. Founded in 2012 and originally known as Six Five Labs, Viv creates a global platform that enables developers to build intelligent conversational interfaces. This universal digital assistant is designed to handle a wide array of spoken requests by integrating with multiple services, allowing users to engage seamlessly with technology. Since May 2014, Viv has operated as a subsidiary of Samsung Research America, continuing its mission to enhance user interaction through advanced AI capabilities.
Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.
Lucira Health develops a new class of professional and home-health solutions to help illuminate and elucidate health status to expedite decision-making and treatment. The company's at-home test kit is well suited for home use and the molecular nucleic acid amplification technology is adaptable to COVID-19 detection. Lucira Health produces inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world. It enables consumers to take the first step in their healthcare management through at-home diagnosis and a companion mobile app to provide follow up treatment. Lucira Health was founded in 2013 and is headquartered in Emeryville, California, United States.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Emerald was founded in 2010 by two scientists and life-long friends from Philadelphia with a singular vision of how a biotechnology company should run. Frustrated by the continual deceleration of innovation and the exponentially increasing R&D costs in the pharmaceutical sector, Emerald models itself after the legendary start-up companies of the mid-20th century that built the core technologies underlying the meteoric rise of the semiconductor industry. The team places as much focus on building tools around how scientific research is conducted as they do on their proprietary anti-viral therapies. In this way, Emerald is striving to bring a Moore’s law-like acceleration to life sciences innovation.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Tempo Automation Inc. is a San Francisco-based electronics manufacturer specializing in the prototyping and low-volume production of printed circuit board assemblies. Founded in 2013, the company leverages a proprietary automation platform that integrates software, data analytics, and advanced manufacturing techniques to enhance speed, precision, and transparency in the development process. This innovative approach creates a seamless digital connection from design to delivery, allowing hardware developers to accelerate innovation and bring new products to market more efficiently. The company's smart factory is designed to optimize the complexities of electronics manufacturing, providing significant advantages in quality and agility for its clients. Tempo Automation is backed by various investors, including venture capital firms and individual investors, who support its mission to transform electronic product development.
Eat Just, Inc. is a San Francisco-based company focused on developing innovative food products aimed at creating a healthier and more sustainable food system. Founded in 2011, the company offers a range of plant-based items, including scrambled eggs, flavored mayonnaise, various dressings, cookie doughs, and meat alternatives. With a strong emphasis on research and culinary expertise, Eat Just combines scientific discovery with culinary innovation, resulting in products that are both delicious and accessible. The company's flagship product, JUST Egg, has received numerous accolades, including recognition as one of Popular Science's "100 Greatest Innovations." Eat Just has been acknowledged for its innovative contributions to the food industry by various organizations, including Fast Company and the World Economic Forum.
Plethora Corporation specializes in the design, manufacturing, and supply of precision machined parts, utilizing advanced robotics and software to enhance CNC machining processes. Established in 2012 and headquartered in San Francisco, California, with an additional office in Marietta, Georgia, the company focuses on the milling and turning of various materials, including aluminum and copper alloys, plastics, steels, and stainless steels. Plethora serves a diverse range of industries, including robotics, automotive, aerospace, and consumer packaged goods, providing custom parts tailored to customer specifications. Its innovative manufacturing system integrates seamlessly with existing CAD and CAM software, allowing for increased efficiency in the production of custom components.
Miroculus, Inc. is a San Francisco-based company that specializes in non-invasive molecular data gathering and analysis tools. Founded in 2014, Miroculus has developed a digital microfluidics platform that automates and miniaturizes genomic protocols, making advanced molecular testing accessible to a wide range of laboratories. Their innovative cartridge-based system allows for the efficient execution of various applications, including next-generation sequencing library preparation, synthetic biology, and cell editing. Miroculus focuses on providing affordable, accurate, and minimally invasive testing solutions that enable medical practitioners to detect and monitor diseases at the molecular level. Their offerings cater to academic institutions, genomic research centers, and companies in the pharmaceuticals, biotechnology, and diagnostics sectors.
uBiome, Inc. is a microbial genomics company based in San Francisco, California, founded in 2012. The company specializes in developing sequencing-based clinical microbiome tests, which include SmartGut, a test that identifies pathogenic and commensal microorganisms linked to infections, and SmartJane, a women's health screening test that assesses multiple conditions such as HPV and STIs. Additionally, uBiome offers Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. The firm aimed to empower patients and healthcare providers by providing insights into the human microbiome and its impact on health. However, uBiome faced financial difficulties, filing for Chapter 11 bankruptcy in September 2019, which was subsequently converted to Chapter 7 on October 11, 2019.
uBiome, Inc. is a microbial genomics company based in San Francisco, California, founded in 2012. The company specializes in developing sequencing-based clinical microbiome tests, which include SmartGut, a test that identifies pathogenic and commensal microorganisms linked to infections, and SmartJane, a women's health screening test that assesses multiple conditions such as HPV and STIs. Additionally, uBiome offers Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. The firm aimed to empower patients and healthcare providers by providing insights into the human microbiome and its impact on health. However, uBiome faced financial difficulties, filing for Chapter 11 bankruptcy in September 2019, which was subsequently converted to Chapter 7 on October 11, 2019.
Vicarious is an artificial intelligence company founded in 2010 by Dr. Dileep George and D. Scott Phoenix, headquartered in San Francisco, California. The company focuses on developing general intelligence for robots by leveraging the computational principles of the human brain. Vicarious aims to tackle significant challenges in the field of AI, fostering a culture that values intellectual curiosity, collaboration, and passion among its team members.
Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.
Cleversafe, Inc. develops Web-scale storage solutions. It offers an enterprise storage solution that enables businesses to store, manage, and access data at petabyte scale and more. The company provides content repository, Storage-as-a-Service, enterprise collaboration, backup, and archive solutions. It serves financial service and insurance, health care and life science, media and entertainment, oil and gas, service provider, and government markets worldwide. The company was founded in 2004 and is based in Chicago, Illinois. As of November 6, 2015, Cleversafe, Inc. operates as a subsidiary of International Business Machines Corporation.
LightSail Energy, a Berkeley, CA-based developer of energy storage technology.